Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Current Deferred Revenue (2024 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Current Deferred Revenue for 2 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 32.4% to $7.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Dec 2025, down 32.4% year-over-year, with the annual reading at $7.5 million for FY2025, 32.4% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $7.5 million at Nuvation Bio, down from $9.1 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $12.9 million in Q3 2024, with the low at $4.5 million in Q2 2025.